Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma
Launched by CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY · Mar 6, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the prevalence of pancreatic steatosis, which means fat build-up in the pancreas, in patients with certain types of pancreatic cysts and pancreatic adenocarcinoma, a type of cancer. Researchers want to find out if having pancreatic steatosis increases the risk of developing these cysts, especially those that could potentially lead to cancer. They are currently recruiting participants aged 18 and older who have at least one pancreatic cyst that is 5mm or larger, as well as healthy individuals or those with confirmed pancreatic adenocarcinoma.
If you or a loved one are considering participating, you should know that eligibility includes being an adult with the specified pancreatic conditions. Participants will undergo imaging tests like CT scans and endoscopic ultrasound (EUS) to assess their condition. However, some people may not be eligible, such as those with certain health issues or significant alcohol consumption. Overall, this trial aims to better understand the relationship between pancreatic fat and the risk of pancreatic diseases, which may help improve patient care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 or older
- • Patients with at least 1 pancreatic cystic lesion based on CT and EUS features, with a cyst size ≥ 5mm; or healthy subjects or PDAC (confirmed by histopathological exam).
- Exclusion Criteria:
- • No evidence of written informed consent
- • Patients with contraindications for endoscopy due to comorbidities
- • Metal stent in hepato-bilio-pancreatic region at time of baseline CT-imaging (vascular, luminal and biliary)
- • Acute pancreatitis at baseline imaging
- • Pancreatic surgery at baseline imaging in our department
- • Splenectomy
- • Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women
About Carol Davila University Of Medicine And Pharmacy
Carol Davila University of Medicine and Pharmacy is a prestigious academic institution located in Bucharest, Romania, renowned for its commitment to advancing medical education, research, and healthcare innovation. As a clinical trial sponsor, the university leverages its extensive research capabilities and experienced faculty to conduct rigorous clinical studies that aim to enhance medical knowledge and improve patient outcomes. With a focus on ethical standards and patient safety, the university collaborates with various stakeholders, including healthcare professionals and industry partners, to foster groundbreaking research that addresses pressing medical challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bucharest, Sector 1, Romania
Bucharest, , Romania
Patients applied
Trial Officials
Mihai Ciocirlan, MD PhD
Study Chair
Romanian Society of Digestive Endoscopy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported